COST-EFFECTIVENESS OF SAXAGLIPTIN (ONGLYZA®) IN TYPE 2 DIABETES IN SOUTH AFRICA

被引：0
|
作者：
Juarez-Garcia, A. [1 ]
Casalvolone, D. [2 ]
Qatami, L. [3 ]
Bergenheim, K. [4 ]
Donato, B. M. K. [5 ]
机构：
[1] Bristol Myers Squibb Co, Mexico City, DF, Mexico
[2] Bristol Myers Squibb Co, Bedforview, South Africa
[3] Bristol Myers Squibb Co, Dubai, U Arab Emirates
[4] AstraZeneca, Molndal, Sweden
[5] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.974
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A180 / A180
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of primary prevention of type 2 diabetes
    Icks, A.
    Chernyak, N.
    Klein, A.
    Brinks, R.
    Genz, J.
    Giani, G.
    DIABETOLOGE, 2011, 7 (02): : 92 - 98
  • [22] COST-EFFECTIVENESS OF EXERCISE PROGRAMS IN TYPE 2 DIABETES
    Coyle, Doug
    Coyle, Kathryn
    Kenny, Glen P.
    Boule, Normand G.
    Wells, George A.
    Fortier, Michelle
    Reid, Robert D.
    Phillips, Penny
    Sigal, Ronald J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (03) : 228 - 234
  • [23] Modelling the Cost-Effectiveness of Hepatitis A in South Africa
    Patterson, Jenna
    Cleary, Susan
    Norman, Jared Michael
    Van Zyl, Heiletje
    Awine, Timothy
    Mayet, Saadiyah
    Kagina, Benjamin
    Muloiwa, Rudzani
    Hussey, Gregory
    Silal, Sheetal Prakash
    VACCINES, 2024, 12 (02)
  • [24] A COST-EFFECTIVENESS ANALYSIS OF ALOGLIPTIN IN COMPARISON TO SAXAGLIPTIN
    Wingate, L. T.
    Oishi, T. S.
    Ali, Shubar N. S.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [25] COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VERSUS METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE-2 DIABETES PATIENTS IN CHILE
    Elgart, J.
    Caporale, J.
    Aiello, E. C.
    Waschbusch, M.
    Jotimliansky, L.
    Gagliardino, J. J.
    Valencia, J. E.
    VALUE IN HEALTH, 2011, 14 (03) : A96 - A96
  • [26] Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
    Bekele, Mengistu
    Norheim, Ole Frithjof
    Hailu, Alemayehu
    MDM POLICY & PRACTICE, 2021, 6 (01)
  • [27] COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VS. METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN ARGENTINA
    Elgart, J.
    Caporale, J.
    Gagliardino, J. J.
    Aiello, E. C.
    Waschbusch, M.
    Jotimliansky, L.
    VALUE IN HEALTH, 2010, 13 (03) : A61 - A61
  • [28] COST-EFFECTIVENESS ANALYSIS OF MASS SCREENING PROGRAM FOR TYPE 2 DIABETES MELLITUS IN SOUTH KOREA
    Jang, S.
    Park, S. M.
    Jo, J. H.
    Yang, D. W.
    Bahk, J. K.
    Hahn, S.
    Lee, T. J.
    VALUE IN HEALTH, 2014, 17 (03) : A135 - A135
  • [29] COST-EFFECTIVENESS OF SAXAGLIPTIN AND LINAGLIPTIN IN COMBINATION WITH METFORMIN FOR TYPE II DIABETES: A DECISION-TREE ANALYSIS MODEL
    Sawant, R., V
    Sansgiry, S. S.
    VALUE IN HEALTH, 2014, 17 (03) : A250 - A251
  • [30] Extended cost-effectiveness analysis of interventions to improve uptake of diabetes services in South Africa
    Fraser, Heather L.
    Feldhaus, Isabelle
    Edoka, Ijeoma P.
    Wade, Alisha N.
    Kohli-Lynch, Ciaran N.
    Hofman, Karen
    Verguet, Stephane
    HEALTH POLICY AND PLANNING, 2024, 39 (03) : 253 - 267
12345